Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Pei-Yong Shi and Camila Fontes-Garfias.
Pei-Yong Shi
Connection Strength
3.471
Camila Fontes-Garfias
  1. Functional Analysis of Glycosylation of Zika Virus Envelope Protein. Cell Rep. 2017 Oct 31; 21(5):1180-1190.
    View in: PubMed
    Score: 0.740
  2. Author Correction: Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2021 Jul; 595(7865):E1.
    View in: PubMed
    Score: 0.238
  3. Author Correction: A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat Commun. 2021 Jun 22; 12(1):4000.
    View in: PubMed
    Score: 0.238
  4. Author Correction: A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. Nat Commun. 2021 Jun 21; 12(1):3984.
    View in: PubMed
    Score: 0.238
  5. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. N Engl J Med. 2021 07 29; 385(5):472-474.
    View in: PubMed
    Score: 0.236
  6. The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. NPJ Vaccines. 2021 Mar 25; 6(1):44.
    View in: PubMed
    Score: 0.234
  7. Neutralizing Activity of BNT162b2-Elicited Serum. N Engl J Med. 2021 04 15; 384(15):1466-1468.
    View in: PubMed
    Score: 0.233
  8. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. 2021 04; 27(4):620-621.
    View in: PubMed
    Score: 0.232
  9. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2021 04; 592(7852):116-121.
    View in: PubMed
    Score: 0.227
  10. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. Nat Commun. 2020 10 15; 11(1):5214.
    View in: PubMed
    Score: 0.227
  11. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat Commun. 2020 08 13; 11(1):4059.
    View in: PubMed
    Score: 0.224
  12. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021 07; 595(7868):572-577.
    View in: PubMed
    Score: 0.059
  13. Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2021 Feb; 590(7844):E17.
    View in: PubMed
    Score: 0.058
  14. Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2021 Feb; 590(7844):E26.
    View in: PubMed
    Score: 0.058
  15. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021 04; 592(7853):283-289.
    View in: PubMed
    Score: 0.058
  16. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020 12 17; 383(25):2439-2450.
    View in: PubMed
    Score: 0.057
  17. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020 10; 586(7830):594-599.
    View in: PubMed
    Score: 0.057
  18. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020 10; 586(7830):589-593.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.